Adaptive Biotechnologies Corp (ADPT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.70B
Last updated: Nov 17, 2026 at 4:33 PM ET
Adaptive Biotechnologies Corp (ADPT) Statistics
Adaptive Biotechnologies (ADPT) has a market cap of $4.70B and an enterprise value of $4.63B. Its share count is up 5.23% from a year earlier. It kept -23.73% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 1.61% below the market cap, as cash exceeds debt.
| Market Cap | $4.70B |
|---|---|
| Enterprise Value | $4.63B |
| Latest price (Nov 17, 2026) | $28.49 |
Key Dates
The next earnings report is expected on Feb 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 15.3x and 25.9x. Its year-end P/S ranged from 4.2x to 81.5x from 2019 to 2025.
| P/S Ratio | 15.3x |
|---|---|
| Forward P/S | 15.3x |
| P/B Ratio | 25.9x |
| P/TBV Ratio | 80.5x |
Price Statistics
The stock is up 102.06% over 52 weeks and trades 5.28% above its 50-day average.
| Beta (1Y) | 1.53 |
|---|---|
| 52-Week Change | +102.06% |
| 1-Month Change | +18.96% |
| 3-Month Change | +11.77% |
| 6-Month Change | +119.83% |
| 5-Year Change | -20.26% |
| Total Return (1Y) | +102.06% |
| Total Return (3Y CAGR) | +87.65% |
| Total Return (5Y CAGR) | -0.08% |
| Return vs SPY (1Y) | +95.64% |
| Max Drawdown (1Y) | -39.35% |
| Max Drawdown (3Y) | -56.19% |
| Sharpe Ratio (1Y) | 1.10 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $27.06 |
| 200-Day Average | $20.19 |
| 52-Week Range | $12.00 to $32.21 |
| RSI (14 Days) | 54.4 |
| Average Volume (20 Days) | 2.31M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.97x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.97x |
|---|---|
| Quick Ratio | 3.87x |
| Debt / Equity | 0.00x |
| Interest Coverage | -1.47x |
Returns and Efficiency
Return on equity is -40.14% over the last 12 months, against a 5-year average of -51.29%.
| Return on Equity (ROE) | -40.14% |
|---|---|
| Return on Assets (ROA) | -10.35% |
| Return on Capital Employed (ROCE) | -8.25% |
| ROE (5Y Average) | -51.29% |
| ROA (5Y Average) | -24.22% |
| ROIC (5Y Average) | -28.37% |
| Asset Turnover | 0.51x |
| Inventory Turnover | 7.50x |
| Receivables Turnover | 5.13x |
| Cash Conversion Cycle | 92 days |
Scores
ADPT has an Altman Z-Score of 3.30, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.30 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $298.01M over the last 12 months is up 17.91% from the 12 months before.
| Revenue | $298.01M |
|---|---|
| Revenue Growth (YoY) | +17.91% |
| Gross Profit | $220.98M |
| Operating Income | -$48.21M |
| Pretax Income | -$70.73M |
| Net Income | -$70.73M |
| EBITDA | -$34.05M |
| EBIT | -$48.21M |
| Reported EPS (TTM) | -$0.30 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 25.79% of the $683.12M in total assets.
| Cash and Equivalents | $75.61M |
|---|---|
| Total Debt | $0 |
| Net Cash | $75.61M |
| Net Cash Per Share | $0.47 |
| Working Capital | $293.72M |
| Shareholder Equity | $176.21M |
| Book Value Per Share | $1.10 |
| Tangible Book Value | $56.78M |
| Tangible Book Per Share | $0.35 |
| Total Assets | $683.12M |
| Total Liabilities | $499.23M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $4.54M of capital spending, operating cash flow left -$8.82M of free cash flow.
| Operating Cash Flow | -$4.28M |
|---|---|
| Capital Expenditures | $4.54M |
| Free Cash Flow | -$8.82M |
| FCF Per Share | -$0.06 |
| Depreciation and Amortization | $14.59M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -16.18%, against a 5-year average of -97.64%.
| Gross Margin | 74.15% |
|---|---|
| Operating Margin | -16.18% |
| Pretax Margin | -23.73% |
| Net Margin | -23.73% |
| EBITDA Margin | -11.43% |
| EBIT Margin | -16.18% |
| FCF Margin | -2.96% |
| Gross Margin (5Y Average) | 65.28% |
| Operating Margin (5Y Average) | -97.64% |
| Net Margin (5Y Average) | -97.08% |
Growth
Revenue grew 14.34% a year over 3 years.
| Revenue Growth (3Y CAGR) | +14.34% |
|---|---|
| Revenue Growth (5Y CAGR) | +23.00% |
| Book Value Per Share Growth (2Y CAGR) | -18.07% |
| Tangible Book Per Share Growth (2Y CAGR) | -29.03% |
Dividends and Yields
ADPT does not pay a dividend. Its free cash flow yield is -0.19%.
| FCF Yield | -0.19% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 12 similar companies, ADPT has the 3rd highest P/S.
P/S RatioPeer median 3.9x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.98%
| P/S Ratio | 15.3x vs 3.9x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +17.91% vs +13.98% median |
Analyst Forecast
Consensus estimates put revenue growth at 16.10% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +16.10% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ADPT
What is ADPT's market cap?
Adaptive Biotechnologies has a market cap of $4.70B. Its enterprise value, which adds debt and subtracts cash, is $4.63B.
How many shares of ADPT are outstanding?
Adaptive Biotechnologies has 160.40M shares outstanding. The count is up 5.23% from a year earlier.
Does ADPT pay a dividend?
No. Adaptive Biotechnologies does not pay a dividend.
How much debt does ADPT have?
Adaptive Biotechnologies has $0 of total debt and $75.61M of cash and equivalents, a net cash position of $75.61M.
ADPT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts